| Restasis (U.S.N.L.M.) | ||
|---|---|---|
| Dosing | 1 drop bid 12 hours apart (Shake emulsion) | |
| Chem Specs | cyclosporine 0.05% | |
| Quantities | 0.4 ml vials, (30 or 60 vials per tray), and 5.5 ml in 10 ml bottle | |
| Cost | 94.00(box of 30 vials), 610.00 5.5ml bottle¹ | |
| Class | peptide immunosuppressant | |
| Action | Calcineurin inhibitor, modulates T-cell function and increases goblet cell density. | |
| Usage | Indicated to increase tear production where tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. |
|
| Increased tear production was not seen in patients concurrently taking topical anti- inflammatory drugs or using punctal plugs. |
||
| Contraindications | Active ocular infections and hypersensitivity to any ingredients in the formulation. | |
| Pediatric use | Safety and efficacy not established in pediatric patients below the age of 16. | |
| Pregnancy | Category C. Teratogenic in rats when administered at 5000x the normal human dose. | |
| Can be used concomitantly with artificial tears, allowing 15 minutes between products. | ||
| 1. Original Restasis patent ruled invalid. 0.09% Cequa and compounded 0.1% Klarity-C now available. Canadian generic: www.mapleleafmeds.com $58.00/30 vials and 3ml bottles for $30.50 |
||